- Home
- ALH vs ACLX Comparison
ALH vs ACLX Comparison
Compare ALH & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALH
- ACLX
- Stock Information
- Founded
- ALH 1908
- ACLX 2015
- Country
- ALH United States
- ACLX United States
- Employees
- ALH N/A
- ACLX N/A
- Industry
- ALH Industrial Machinery/Components
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- ALH Industrials
- ACLX Health Care
- Exchange
- ALH Nasdaq
- ACLX Nasdaq
- Market Cap
- ALH 5.4B
- ACLX 4.4B
- IPO Year
- ALH 2025
- ACLX 2022
- Fundamental
- Price
- ALH $26.35
- ACLX $86.08
- Analyst Decision
- ALH Strong Buy
- ACLX Strong Buy
- Analyst Count
- ALH 8
- ACLX 10
- Target Price
- ALH $31.50
- ACLX $117.50
- AVG Volume (30 Days)
- ALH 1.0M
- ACLX 402.5K
- Earning Date
- ALH 11-13-2025
- ACLX 11-05-2025
- Dividend Yield
- ALH N/A
- ACLX N/A
- EPS Growth
- ALH N/A
- ACLX N/A
- EPS
- ALH 0.45
- ACLX N/A
- Revenue
- ALH $1,616,188,000.00
- ACLX $35,898,000.00
- Revenue This Year
- ALH N/A
- ACLX N/A
- Revenue Next Year
- ALH N/A
- ACLX $220.95
- P/E Ratio
- ALH $58.46
- ACLX N/A
- Revenue Growth
- ALH 17.43
- ACLX N/A
- 52 Week Low
- ALH $23.50
- ACLX $47.86
- 52 Week High
- ALH $27.33
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- ALH N/A
- ACLX 52.73
- Support Level
- ALH N/A
- ACLX $84.00
- Resistance Level
- ALH N/A
- ACLX $90.30
- Average True Range (ATR)
- ALH 0.00
- ACLX 3.57
- MACD
- ALH 0.00
- ACLX -0.31
- Stochastic Oscillator
- ALH 0.00
- ACLX 42.53
About ALH Alliance Laundry Holdings Inc. Common Stock
Alliance Laundry Holdings Inc is designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.